Sulekha Suresh Dhanisha, Jain Tejeshwar, Dudeja Vivaan, Iyer Srikanth, Dudeja Vikas
Division of Surgical Oncology, Department of Surgery, The University of Alabama at Birmingham, BDB 573 1808 7th Avenue South, Birmingham, AL 35294, USA.
Int J Mol Sci. 2025 Mar 28;26(7):3112. doi: 10.3390/ijms26073112.
Pancreatic cancer is a major cause of cancer-associated mortality globally, characterized by a poor prognosis and limited therapeutic response. The current approach for treating pancreatic cancer involves locoregional control with surgical resection and systemic therapy in the form of cytotoxic chemotherapy. However, despite standard-of-care treatment, the outcomes remain dismal. Emerging evidence suggests that the gut microbiota plays a significant role in pancreatic carcinogenesis through dysbiosis, chronic inflammation and immune modulation. Dysbiosis-driven alterations in the gut microbiota composition can disrupt intestinal homeostasis, promote systemic inflammation and create a tumor-permissive microenvironment in the pancreas. Moreover, the gut microbiota modulates the efficacy of systemic therapies, including chemotherapy and immunotherapy, by impacting drug metabolism and shaping the tumor immune landscape. This review is mainly focused on exploring the intricate interplay between the gut microbiota and pancreatic cancer, and also highlighting its dual role in carcinogenesis and the therapeutic response.
胰腺癌是全球癌症相关死亡的主要原因，其特点是预后不良且治疗反应有限。目前治疗胰腺癌的方法包括通过手术切除进行局部区域控制以及采用细胞毒性化疗形式的全身治疗。然而，尽管采用了标准治疗方案，治疗结果仍然令人沮丧。新出现的证据表明，肠道微生物群通过生态失调、慢性炎症和免疫调节在胰腺癌发生过程中发挥重要作用。肠道微生物群组成的生态失调驱动的改变会破坏肠道稳态，促进全身炎症，并在胰腺中创造一个有利于肿瘤生长的微环境。此外，肠道微生物群通过影响药物代谢和塑造肿瘤免疫格局来调节全身治疗（包括化疗和免疫治疗）的疗效。本综述主要聚焦于探索肠道微生物群与胰腺癌之间的复杂相互作用，并强调其在致癌作用和治疗反应中的双重作用。
